Geron 3Q 2026: Revenue $60.19M, Net income $1.35M, EPS $0— 10-Q Summary

What happened

Geron reported third-quarter 2026 revenue of $60.19 million, up 27.4% from a year earlier, and net income of $1.35 million, versus a net loss of $18.43 million. Diluted earnings per share were $0, compared with a loss of $0.03 a year earlier. RYTELO product revenue rose 27% to $60.1 million.

Confirmed

Global impact / market context

The return to a small profit alongside higher RYTELO sales suggests improved operating performance, but the company says continued U.S. sales growth is uncertain and may require commercial strategy changes. That uncertainty could affect future revenue and the resources Geron directs toward selling the drug.

Analyst inference

Geron is pairing commercial growth with a narrower research focus after discontinuing its Phase 3 IMpactMF trial because an independent committee judged it unlikely to meet its overall-survival goal. Focusing on lower-risk MDS may concentrate research spending, while the selected-market European launch remains gradual.

Analyst inference

What to watch

1. Track quarterly RYTELO revenue and U.S. sales volume, since the company attributes growth mainly to more accounts and patients receiving therapy, with price increases contributing less. Analyst inference
2. Watch for the expected RYTELO availability in Germany by the end of 2026 and France in 2027; these are company expectations, not completed launches. Confirmed
3. Look for updates on commercial strategy and spending on lower-risk MDS research, which could show how Geron responds to uncertain sales growth and the stopped trial. Analyst inference

Evidence

• Original source link unavailable